Tyr972
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr972  -  JAK2 (human)

Site Information
EyLGTkRyIHRDLAT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 470145

In vivo Characterization
Methods used to characterize site in vivo:
phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 1 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 )
Relevant cell line - cell type - tissue:
HEL (erythroid) ( 1 ) , T lymphocyte ( 1 )

Upstream Regulation
Treatments:
fingolimod ( 1 )

Downstream Regulation
Effects of modification on JAK2:
activity, induced ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )

References 

1

Oaks JJ, et al. (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122, 1923-34
23926298   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.